Valerie L. Pierce serves as Senior Vice President, Chief Compliance Officer, General Counsel, Secretary of the Company. She brings more than 25 years of experience providing broad legal guidance and leadership to public pharmaceutical and biotechnology companies. She joins NGM from Jazz Pharmaceuticals, where she worked since 2012, most recently as Senior Vice President, Associate General Counsel. Before Jazz, Ms. Pierce worked as Vice President and Senior Transactional Counsel at Amyris, Inc., Senior Vice President and General Counsel at Sunesis Pharmaceuticals, Inc. and in various in-house legal positions at the Institute for OneWorld Health, Tularik Inc. and ALZA Corporation. Ms. Pierce received a B.A. from Yale University and a J.D. from the Yale Law School.
Valerie's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel и Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: